Should hydroxyethyl starch be banned?
In their Correspondence in The Lancet, Ian Roberts and colleagues (Feb 12, p 736) 1 ask the director general of WHO to ban the use of hydroxyethyl starch (HES) solutions worldwide "to protect patients". Several clarifi cations and corrections are needed to place the authors' arguments into proper perspective.
Roberts and colleagues 1 state that evidence from highquality trials in kidney donors and in patients who are critically ill and septic has shown that the use of HES is associated with serious adverse effects without benefits. They reference the study by Myburgh and colleagues 2 in support of this statement. With respect to the claim that the trial was high quality, numerous aspects of Myburgh and colleagues' study have been repeatedly criticised (including changes in the methods, statistical analysis, and data after publication, and questionable data interpretation), which resulted in a call to the authors to open the trial data for independent reanalysis. 3, 4 The authors refused to do so. Of note, the first three authors of this trial are co authors of the Correspondence. 1 With respect to the claim that HES causes adverse effects, in Myburgh and colleagues' trial, 2 significantly more patients in the saline group met risk, injury, failure, loss, and endstage kidney injury (RIFLE) criteria for kidney dysfunction than did those in the HES group (57·3% vs 54·0%; p=0·007). Likewise, RIFLEdefined renal injury occurred significantly more often in the saline group than in the HES group (38·0% vs 34·6%; p=0·005). No significant difference was seen between the groups in the occurrence of RIFLE defined renal failure (9·2% vs 10·4%; p=0·12).
Careful interpretation of existing data is needed. A systematic review 5 of studies comparing the effects of HES on renal function with other fluids showed that in patients who were nonseptic, HES was not associated with an increased incidence of renal replacement therapy (risk ratio 1·25, 95% CI 0·96-1·61), renal failure (1·32, 1·15-1·53), or RIFLEdefined renal failure (1·04, 0·86-1·27). HES was even associated with a lower incidence of RIFLEdefined renal injury or worse (ie, loss of renal function or endstage renal disease) than were other fluids (0·85, 0·78-0·92). 5 That the effects of HES differ with the underlying medical condition and the indication for its use is to be expected.
Roberts and colleagues 1 state that during the WOMAN trial 6 they became aware that many women with postpartum haemorrhage received colloids and, most often, HES. In that trial, 5714 (28·5%) of 20 060 patients had an estimated blood loss of 1-1·5 L, 3926 (19·6%) had an estimated blood loss of more than 1·5 L, and 3839 (19·1%) had a systolic blood pressure of less than 90 mm Hg. For most physicians working in acute or perioperative care, these complications are a clear indication for administration of colloids. Because albumin, gelatine, and dextran are either not available or considered inappropriate in many countries, the use of HES under such circumstances is to be expected. That HES contributed to the haemodynamic stabilisation of numerous women in acute severe haemorrhagic hypo tension is quite possible. Furthermore, the use of HES in such settings is entirely in agreement with the 2013 European Medicines Agency (EMA) recommendations, which state that "HES solutions should only be used for treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient". 7 Roberts and colleagues 1 also state that WHO guidelines recommend the use of crystalloids in preference to colloids for the resuscitation of women with postpartum haemorrhage. However, the 2017 WHO recommendation on tranexamic acid for the treat ment of postpartum haemorrhage, which the authors cite, states that "standard care in the context of this recommend ation includes routine care for PPH [postpartum haemorrhage] treatment, including fluid replacement". 8 The types of fluids are not specified. Only the 2012 WHO guideline recommended the use of intravenous fluid replacement with isotonic crystalloids in preference to colloids, including the clarification that this recommendation was based on lowquality evidence.
Upon request from the Pharma covigilance Risk Assessment Com mittee (PRAC), the EMA convened an adhoc expert meeting in London on Dec 18, 2017. 9 After hearing and evaluating the views of the PRAC rapporteur and corapporteur, and of the marketing authorisation holders, the experts recommended that PRAC do not completely suspend HES solutions. They concluded that HEScontaining solutions have a place under certain conditions, espe cially in patients with hypovolaemia caused by acute bleeding. The experts expressed concerns regarding potential alternative colloid solutions (eg, albumins, dextrans, and gelatines) because of their limited use and the absence of comparative data. The experts strongly recommend ed that HEScontaining solutions should not be suspended before the results of the multi centre PHOENICS (NCT03278548) and TETHYS (NCT03338218) trials become available. Both are prospective, random ised, controlled, doubleblind, parallelgroup, multinational phase 4 trials done under the auspices of the European Society of Anaesthesiology. The trials will provide clinically relevant information regarding the safety and efficacy of a 6% HES solution (molecular weight 130 kDa) versus a balanced crystalloid solution in patients undergoing major elective abdominal surgery (PHOENICS) or in trauma patients (TETHYS). Of note, the EMA itself requested such clinical trials in surgical and trauma patients after the use of HEScontaining solutions had been restricted in 2013. Importantly, only one of the seven experts opposed the use of HES. For unknown reasons, such a questionable basis. The EMA ignored increasing evidence indicating that starches seem to positively affect patient outcomes, and actively decided against waiting for the results of two large randomised controlled trials (initiated by EMA themselves) investigating the safety and efficacy of HES in the context of surgery and trauma (NCT03338218 and NCT03278548).
Speculation from Roberts and col leagues that manufacturers of HES might be putting vulnerable patients in lowincome countries at risk in the future distracts from the real major global health issue: clinical decisions in Europe are no longer based on data and scientific debate but on majority decisions made by authorities.
none of the experts' recommendations and suggestions are mentioned in the PRAC decision. Furthermore, although the PRAC recommendation is easily accessible on the EMA website, 10 the minutes of the adhoc expert group meeting are not. Members of the EMA expert group reiterated the plea to make the CHEST data 2 available for independent reanalysis.
Publications continue to document the absence of increased risk 11, 12 and even the improved outcomes 13 associated with the use of HES under defined clinical circumstances. I entirely agree with the experts' view 9 that complete suspension of HES is not only unfounded by existing evidence, but would be hazardous to patients.
Roberts and colleagues' 1 Corres pondence in
The Lancet asking WHO to support a ban on the use of hydroxyethyl starch (HES) deserves clarification. First, registration of HES is not yet suspended; a legally binding decision by the European Commission is still pending. Second, Roberts and colleagues claim that HES was used to treat postpartum haemorrhage in the WOMAN trial. 2 In fact, the publication doesn't provide any information about HES treatment or its related adverse events. Third, the authors refer to their own studies as examples of highquality trials, but these have been publicly criticised for methodological deficiencies and severe limitations. 3 Notably, several inconsistencies have prompted medical societies and journals to ask for open access of CHEST data, 4,5 unfortunately without success. The socalled independent reanalysis of this study was published by the original authors themselves. 6 19 European national anaesthesiological societies expressed their surprise and dis agreement when the European Medicines Agency (EMA) rushed the farreaching recommendation to suspend the registration of HES on
